Safety of Fluralaner Chewable Tablets Bravecto® in Dogs with Dermatitis–Clinical Pathology Parameters Evaluation
Medication selection should always take into account the fact that therapeutic efficiency means obtaining a pharmacologic response with the desired intensity and duration of drug action, while avoiding adverse reactions. In the case of fluralaner, adverse reactions are mild and transitory gastrointe...
Saved in:
| Main Authors: | Adriana AMFIM, Livia Cătălina BERCEA, Mihaela ZAHARIA |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AcademicPres
2025-05-01
|
| Series: | Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca: Veterinary Medicine |
| Subjects: | |
| Online Access: | https://journals.usamvcluj.ro/index.php/veterinary/article/view/15121 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical efficacy and safety of a single administration of fluralaner injectable suspension (BRAVECTO® injectable) vs. monthly administration of oral afoxolaner (NexGard®) in dogs for tick and flea control over one year under European field conditions
by: Ivo Petersen, et al.
Published: (2024-12-01) -
Fluralaner injectable suspension (Bravecto® injectable) for dogs remains effective against Ixodes ricinus infestations for one-year
by: Georg von Samson-Himmelstjerna, et al.
Published: (2025-08-01) -
A systematic review of fluralaner as a treatment for ectoparasitic infections in mammalian species
by: Yuanting Jiang, et al.
Published: (2025-03-01) -
Pharmacokinetics and safety of topical fluralaner in koalas (Phascolarctos cinereus)
by: Ellyssia T. Young, et al.
Published: (2024-12-01) -
Inhibitory Effect of Fluralaner on GABA Receptor Subunit RDL of <i>Bactrocera dorsalis</i>
by: Xiangyi Zhou, et al.
Published: (2025-05-01)